Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update [Yahoo! Finance]
Chimerix, Inc. (CMRX)
Last chimerix, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.chimerix.com/investor-relations
Company Research
Source: Yahoo! Finance
– No Dose Limiting Toxicity in ONC206 Phase 1 Studies to Date, Preliminary Phase 1 Safety and Pharmacokinetic (PK) Data Expected This Summer – – Company to Advance Dordaviprone in Provisional Registration Process Following Positive Interaction with Therapeutic Goods Administration (TGA) in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the first quarter ended March 31, 2024 and provided an operational update. “Patients, caregivers and physicians are in desperate need for novel therapies that offer clinical benefit in H3 K27M-mutant diffuse glioma, and we believe that dordaviprone (ONC201) has the potential to be a major therapeutic advance in the treatment of this disease,” said Mike Andriole, Chief Executive Off
Show less
Read more
Impact Snapshot
Event Time:
CMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMRX alerts
High impacting Chimerix, Inc. news events
Weekly update
A roundup of the hottest topics
CMRX
News
- Chimerix, Inc. (NASDAQ: CMRX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Chimerix, Inc. (NASDAQ: CMRX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Chimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Chimerix GAAP EPS of -$0.25 [Seeking Alpha]Seeking Alpha
- Chimerix Reports First Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewswire
CMRX
Earnings
- 5/1/24 - Miss
CMRX
Analyst Actions
- 3/1/24 - HC Wainwright
CMRX
Sec Filings
- 5/6/24 - Form EFFECT
- 5/1/24 - Form 10-Q
- 5/1/24 - Form 8-K
- CMRX's page on the SEC website